相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nucleic acid therapeutics: basic concepts and recent developments
Vivek K. Sharma et al.
RSC ADVANCES (2014)
Effects of miR-155 Antisense Oligonucleotide on Breast Carcinoma Cell Line MDA-MB-157 and Implanted Tumors
Shu-Rong Zheng et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2013)
C3′-endo-puckered pyrrolidine containing PNA has favorable geometry for RNA binding: Novel ethano locked PNA (ethano-PNA)
Anjan Banerjee et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Locked nucleic acid: tighter is different
Jonathan K. Watts
CHEMICAL COMMUNICATIONS (2013)
Mipomersen Sodium: First Global Approval
Philip Hair et al.
DRUGS (2013)
Sequential induction of type I and II interferons mediates a long-lasting gene induction in the liver in response to a novel toll-like receptor 9 agonist
Zuzanna Makowska et al.
JOURNAL OF HEPATOLOGY (2013)
Design and Synthesis of LNA-Based Mercaptoacetamido-Linked Nucleoside Dimers
Vivek K. Sharma et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2013)
Synthesis and Biophysical Properties of Constrained D-Altritol Nucleic Acids (cANA)
Michael T. Migawa et al.
ORGANIC LETTERS (2013)
Guideline of transthyretin-related hereditary amyloidosis for clinicians
Yukio Ando et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Development of Novel Bioanalytical Methods to Determine the Effective Concentrations of Phosphorodiamidate Morpholino Oligomers in Tissues and Cells
Frederick J. Schnell et al.
BIORESEARCH OPEN ACCESS (2013)
Hybridizing ability and nuclease resistance profile of backbone modified cationic phosphorothioate oligonucleotides
S. M. Abdur Rahman et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia
Jorge Cortes et al.
CANCER (2012)
RNA-Based Therapeutics: Current Progress and Future Prospects
John C. Burnett et al.
CHEMISTRY & BIOLOGY (2012)
Emerging drugs for Duchenne muscular dystrophy
Vinod Malik et al.
EXPERT OPINION ON EMERGING DRUGS (2012)
Novel targeted therapies for eosinophilic disorders
Michael E. Wechsler et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Discovering the first microRNA-targeted drug
Morten Lindow et al.
JOURNAL OF CELL BIOLOGY (2012)
Efficacy of a Phosphorodiamidate Morpholino Oligomer Antisense Compound in the Inhibition of Corneal Transplant Rejection in a Rat Cornea Transplant Model
Alireza Hosseini et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2012)
Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer
Janessa J. Laskin et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat
Claudia Carrieri et al.
NATURE (2012)
Phosphorothioate DNA as an antioxidant in bacteria
Xinqiang Xie et al.
NUCLEIC ACIDS RESEARCH (2012)
Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy
Mary P. McGowan et al.
PLOS ONE (2012)
The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease
Petra Jilma-Stohlawetz et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Renal uptake and tolerability of a 2′-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey
Scott P. Henry et al.
TOXICOLOGY (2012)
Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections
Patrick L. Iversen et al.
VIRUSES-BASEL (2012)
Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals
Punit P. Seth et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2012)
Pharmacodynamics and Subchronic Toxicity in Mice and Monkeys of ISIS 388626, a Second-Generation Antisense Oligonucleotide That Targets Human Sodium Glucose Cotransporter
Thomas A. Zanardi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Dose-Ranging Evaluation of Intravitreal siRNA PF-04523655 for Diabetic Macular Edema (the DEGAS Study)
Quan Dong Nguyen et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2012)
Metabolism, Pharmacokinetics, Tissue Distribution, and Stability Studies of the Prodrug Analog of an Anti-Hepatitis B Virus Dinucleoside Phosphorothioate
John E. Coughlin et al.
DRUG METABOLISM AND DISPOSITION (2012)
Biochemical Modulation of Aracytidine (Ara-C) Effects by GTI-2040, a Ribonucleotide Reductase Inhibitor, in K562 Human Leukemia Cells
Ping Chen et al.
AAPS JOURNAL (2011)
Delayed Graft Function in the Kidney Transplant
A. Siedlecki et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide
Sophie Callies et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
An Overview of Sugar-Modified Oligonucleotides for Antisense Therapeutics
Thazha P. Prakash
CHEMISTRY & BIODIVERSITY (2011)
A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer
David S. Hong et al.
CLINICAL CANCER RESEARCH (2011)
The Antisense Oligonucleotide Trabedersen (AP 12009) for the Targeted Inhibition of TGF-β2
Frank Jaschinski et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2011)
Chemical Modification of siRNA Bases To Probe and Enhance RNA Interference
Hayden Peacock et al.
JOURNAL OF ORGANIC CHEMISTRY (2011)
Phase II Study of the Novel Peptide-Nucleic Acid OHR118 in the Management of Cancer-Related Anorexia/Cachexia
Martin Chasen et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2011)
The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia
J. Duerig et al.
LEUKEMIA (2011)
OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer
V. Baylot et al.
CELL DEATH & DISEASE (2011)
RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027
Peter K. Kaiser et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2010)
RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
C. Frank Bennett et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial
Paul G. Richardson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Effect of 3′-end capping of aptamer with various 2′,4′-bridged nucleotides: Enzymatic post-modification toward a practical use of polyclonal aptamers
Yuuya Kasahara et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Clinical status of duplex RNA
Jonathan K. Watts et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
Youn H. Kim et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)
Aptamers as therapeutics
Anthony D. Keefe et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Down-Modulation of Survivin Expression and Inhibition of Tumor Growth In Vivo by EZN-3042, A Locked Nucleic Acid Antisense Oligonucleotide
Puja Sapra et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2010)
Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors
Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Study of the c-raf-1 Antisense Oligonucleotide ISIS 5132 in Combination with Carboplatin and Paclitaxel in Patients with Previously Untreated, Advanced Non-small Cell Lung Cancer
Panos Fidias et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
GS-101 Antisense Oligonucleotide Eye Drops Inhibit Corneal Neovascularization Interim Results of a Randomized Phase II Trial
Claus Cursiefen et al.
OPHTHALMOLOGY (2009)
COMBINATION THERAPY USING THE SMALL INTERFERING RNA BEVASIRANIB
Lawrence Singerman
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2009)
Antisense treatment for myasthenia gravis - Experience with Monarsen
Jon D. Sussman et al.
MYASTHENIA GRAVIS AND RELATED DISORDERS: 11TH INTERNATIONAL CONFERENCE (2008)
Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)
John DeVincenzo et al.
ANTIVIRAL RESEARCH (2008)
Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer
Alan I. So et al.
CLINICAL CANCER RESEARCH (2008)
A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth
Lee M. Greenberger et al.
MOLECULAR CANCER THERAPEUTICS (2008)
c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model
Harmanjatinder S. Sekhon et al.
LUNG CANCER (2008)
Triazole-linked analogue of deoxyribonucleic acid (TLDNA):: Design, synthesis, and double-strand formation with natural DNA
Hiroyuki Isobe et al.
ORGANIC LETTERS (2008)
Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy
Robert J. Amato
CLINICAL GENITOURINARY CANCER (2007)
Synthetic agonists of Toll-like receptors 7, 8 and 9
S. Agrawal et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy
Mazin Barry et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
CPG-7909 (PF-3512676, ProMune®):: toll-like receptor-9 agonist in cancer therapy
Yanal M. Murad et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Synthesis and RNA binding selectivity of oligonucleotides modified with five-atom thioacetamido nucleic acid backbone structures
Khirud Gogoi et al.
ORGANIC LETTERS (2007)
Oxepane nucleic acids: Synthesis, characterization, and properties of oligonucleotides bearing a seven-membered carbohydrate ring
David Sabatino et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2007)
A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease
Bruce Yacyshyn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Edifoligide: A transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass
Andrew W. Hoel et al.
CARDIOVASCULAR DRUG REVIEWS (2007)
2 '-modified oligonucleotides for antisense therapeutics
Thazha P. Prakash et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007)
RNA-binding affinities and crystal structure of oligonucleotides containing five-atom amide-based backbone structures
Pradeep S. Pallan et al.
BIOCHEMISTRY (2006)
A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers
S Goel et al.
INVESTIGATIONAL NEW DRUGS (2006)
Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice
D Trabattoni et al.
VACCINE (2006)
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
EWM Ng et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients
JG McHutchison et al.
JOURNAL OF HEPATOLOGY (2006)
Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers
A Amantana et al.
CURRENT OPINION IN PHARMACOLOGY (2005)
Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption
YF Guan et al.
NATURE MEDICINE (2005)
Arginine-rich peptide conjugation to morpholino oligomers: Effects on antisense activity and specificity
MH Nelson et al.
BIOCONJUGATE CHEMISTRY (2005)
Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention
H Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Quantification of raf antisense oligonucleotide (rafAON) in biological matrices by LC-MS/MS to support pharmacokinetics of a liposome-entrapped rafAON formulation
JL Johnson et al.
BIOMEDICAL CHROMATOGRAPHY (2005)
Antisense oligonucleotides: The state of the art
T Aboul-Fadl
CURRENT MEDICINAL CHEMISTRY (2005)
Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas
SA Grossman et al.
NEURO-ONCOLOGY (2005)
Development and validation of a sensitive, specific, and rapid hybridization-ELISA assay for determination of concentrations of a ribozyme in biological matrices
P Brown-Augsburger et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2004)
Spirocyclic restriction of nucleosides
LA Paquette
AUSTRALIAN JOURNAL OF CHEMISTRY (2004)
A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice
AP McCaffrey et al.
HEPATOLOGY (2003)
Synthesis of 2 '-spiro ribo- and arabinonucleosides
BR Babu et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2003)
Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α
KL Sewell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism
V Arora et al.
DRUG METABOLISM AND DISPOSITION (2002)
Synthesis and conformation of 3′,4′-BNA monomers, 3′-O,4′-C-methyleneribonucleosides
S Obika et al.
TETRAHEDRON (2002)
A simplified and efficient route to 2′-O, 4′-C-methylene-linked bicyclic ribonucleosides (locked nucleic acid)
AA Koshkin et al.
JOURNAL OF ORGANIC CHEMISTRY (2001)
Backbone modification of nucleic acids: Synthesis, structure and therapeutic applications
J Micklefield
CURRENT MEDICINAL CHEMISTRY (2001)
Cyclohexene nucleic acids (CeNA) form stable duplexes with RNA and induce RNase H activity
J Wang et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2001)
Potential roles of antisense technology in cancer chemotherapy
ST Crooke
ONCOGENE (2000)
Heterocyclic modifications of oligonucleotides and antisense technology
P Herdewijn
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2000)
分享论文
